This 2016 review explores betulinic acid (BA), a pentacyclic triterpene, as a multifaceted agent against breast cancer. BA inhibits cell proliferation by downregulating cyclins and topoisomerases, leading to cell cycle arrest. It induces apoptosis via the mitochondrial pathway and exhibits anti-angiogenic effects by suppressing NF-κB, Sp transcription factors, and VEGF
